Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Millennium Management LLC

Millennium Management LLC raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 38.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 185,918 shares of the specialty pharmaceutical company's stock after purchasing an additional 51,972 shares during the period. Millennium Management LLC owned 0.58% of Collegium Pharmaceutical worth $5,327,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of COLL. New Age Alpha Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $40,000. KBC Group NV increased its position in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock valued at $196,000 after acquiring an additional 642 shares in the last quarter. Finally, FORA Capital LLC acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at $223,000.

Collegium Pharmaceutical Trading Up 0.7%

Shares of NASDAQ COLL traded up $0.21 on Friday, reaching $29.39. 212,597 shares of the company traded hands, compared to its average volume of 422,576. The stock has a market capitalization of $944.36 million, a PE ratio of 12.67 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a 50 day moving average of $28.01 and a 200 day moving average of $29.60.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period last year, the company posted $1.45 EPS. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Colleen Tupper sold 977 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares in the company, valued at approximately $4,928,070. The trade was a 0.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

COLL has been the subject of several analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler reiterated a "neutral" rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.